**Supplemental Digital Content 6.** Incidence of unsolicited adverse events post-vaccination (total vaccinated cohort at Month 73)

| | HibMenC group | Hib+MCC group |
|---|---|---|
| N | 119 | 37 |
| Any unsolicited AE* | 36 (30.3%) | 7 (18.9%) |
| Related to vaccination | 8 (6.7%) | 0 |
| Grade 3 | 8 (6.7%) | 2 (5.4%) |
| Grade 3 related to vaccination | 1 (0.8%) | 0 |
| New onset of chronic illness* | 0 | 0 |
| Any SAE* | 0 | 0 |
| SAE related to vaccination** | 0 | 0 |
| Fatal SAE** | 0 | 0 |

N, number of participants; AE, adverse event; SAE, serious adverse event. *Recorded after vaccination up to 31 days. **Recorded after vaccination until the study end.

Note: HibMenC group, received *Haemophilus influenzae* type b-meningococcal serogroup C-tetanus toxoid conjugate (HibMenC-TT) and measles, mumps and rubella (MMR) vaccines in the primary study and meningococcal serogroups A, C, W, Y-tetanus toxoid conjugate vaccine (MenACWY-TT) in the extension study; Hib+MCC group, received *Haemophilus influenzae* type b conjugated to tetanus toxoid (Hib-TT), meningococcal serogroup C conjugated to $CRM_{197}$ (MCC-$CRM_{197}$) and MMR vaccines in the primary study and MenACWY-TT in the extension study. Month 73, 1 month post-vaccination. Grade 3 was considered if an AE prevented normal, everyday activities. An AE was considered as related to vaccination if the causality was assessed and determined by an investigator.